Stockscreener 앱 받기
33.88
1.19%
-0.425
전일 마감가:
$34.31
열려 있는:
$34.35
하루 거래량:
2.21M
Relative Volume:
0.21
시가총액:
$39.48B
수익:
$17.41B
순이익/손실:
$1.43B
주가수익비율:
27.82
EPS:
1.2182
순현금흐름:
$1.00B
1주 성능:
-2.59%
1개월 성능:
+3.39%
6개월 성능:
+104.22%
1년 성능:
+107.47%
1일 변동 폭
$33.77
$34.35
1주일 범위
$33.77
$35.11
52주 변동 폭
$12.46
$37.34
테바 ADR Stock (TEVA) Company Profile
명칭
Teva Pharmaceutical Industries Ltd Adr
전화
972 (3) 914-8213
주소
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, ZTS, HLN, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.90 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.30 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.14 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.14 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
UTHR
United Therapeutics Corp
|
474.49 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
테바 ADR Stock (TEVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-12-05 | 개시 | Scotiabank | Sector Outperform |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-05-28 | 개시 | Truist | Buy |
| 2025-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-07-10 | 업그레이드 | Argus | Hold → Buy |
| 2024-03-08 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-01-03 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-11-27 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-06 | 업그레이드 | UBS | Sell → Neutral |
| 2023-05-25 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-18 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-01-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-06-14 | 재개 | UBS | Neutral |
| 2022-05-17 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-05-04 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-03-25 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | 다운그레이드 | Argus | Buy → Hold |
| 2021-10-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | 개시 | Oppenheimer | Perform |
| 2020-08-06 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-07-27 | 재개 | Goldman | Neutral |
| 2020-06-01 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-04-24 | 재개 | Citigroup | Neutral |
| 2020-04-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Edward Jones | Hold → Sell |
| 2019-11-12 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-10-17 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-08-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-19 | 개시 | Wolfe Research | Peer Perform |
| 2019-07-15 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-07-05 | 업그레이드 | Argus | Hold → Buy |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-06-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-30 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2019-03-07 | 재개 | UBS | Buy |
모두보기
테바 ADR 주식(TEVA)의 최신 뉴스
Teva Pharmaceutical Industries (NYSE:TEVA) Valuation In Focus Amid Momentum - Kalkine Media
Here's What Analysts Are Saying About Teva Pharmaceutical (TEVA) Post Earnings - Finviz
Tetracyclines Market is Poised to Garner Valuation of USD 5.63 Billion by 2035 | Astute Analytica - GlobeNewswire Inc.
A Look Into Teva Pharmaceutical Indus Inc's Price Over Earnings - Sahm
Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat - Finviz
Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Sahm
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory - Finviz
Teva Canada Mayzent Deal Supports Neuroscience Focus And Valuation Debate - Sahm
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Earnings call transcript: Teva Q4 2025 earnings beat expectations, stock rises - Investing.com
Assessing Teva Pharmaceutical Industries’ Valuation After Strong 2025 Earnings And Analyst Upgrades - Sahm
Teva (TEVA) Is Up 7.1% After 2025 Earnings Highlight Branded-Drugs Momentum And Pipeline Progress - Sahm
Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds - Finviz
Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis - Finviz
Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 92% One-Year Share Price Surge - Sahm
Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 12-Month High Following Earnings Beat - Defense World
Teva Balances Huntington’s Disease Outreach With Branded Drug Transformation - Sahm
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
What Makes Teva Pharmaceuticals (TEVA) a Successful Brand? - Finviz
Teva Pharma stock hits 52-week high at 33.42 USD By Investing.com - Investing.com Nigeria
Teva Pharma stock hits 52-week high at 33.42 USD - Investing.com
Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Margin Recovery Challenges High P/E Valuation Narrative - Sahm
Teva To See Generics Loss From Revlimid in 2026, but Innovative Portfolio Drives Margin Expansion - morningstar.com
Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook - Sahm
Earnings call transcript: Teva beats Q4 2025 EPS forecast, stock dips - Investing.com
Assessing Teva (TEVA) Valuation As Guidance Driven Momentum Lifts Long Term Profit Expectations - Sahm
The Truth About Teva Pharmaceutical (ADR): Why Everyone Is Suddenly Watching This Stock - AD HOC NEWS
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results? - Finviz
Sodium Chloride Injections Market, Global Forecast 2026-2032 - GlobeNewswire Inc.
This pharma stock “is beating everything”, investor says - Cantech Letter
How Long-Term Profit Targets and TEV-‘408 Funding At Teva Pharmaceutical (TEVA) Has Changed Its Investment Story - Sahm
Is Teva (TEVA) Still Reasonably Priced After A 195% Three Year Share Price Gain - Sahm
Assessing Teva Pharmaceutical Industries (TEVA) Valuation After A Sharp Multi‑Month Share Price Rally - Sahm
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Finviz
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug - Sahm
Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32 - Finviz
Should Teva’s Q3 Beat and New Schizophrenia and Denosumab Moves Require Action From TEVA Investors? - Sahm
Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 49% One Year Share Price Jump - Sahm
Teva stock hits 52-week high at $32.02 - Investing.com
Teva Pharmaceutical Industries (NYSE:TEVA): Assessing Valuation After a 46% Share Price Rebound - Sahm
Top 2 Health Care Stocks That May Crash In Q1 - Sahm
Teva Pharmaceutical (ADR) Is Popping Off: Smart Buy or Overhyped Trap? - AD HOC NEWS
Teva Pharmaceutical (ADR): Bracing For 2026 After A Volatile Year Of Legal Wins, Debt Cuts And A Re- - AD HOC NEWS
The Truth About Teva Pharmaceutical (ADR): Is Wall Street Sleeping on This Comeback Play? - AD HOC NEWS
The Truth About Teva Pharmaceutical (ADR): Is This ‘Boring’ Stock Quietly Going Viral with Inves - AD HOC NEWS
What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)? - Finviz
Has Teva’s Surging Share Price Outpaced Its Long Term Recovery Prospects? - Sahm
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive - Sahm
테바 ADR (TEVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.13%
0.14%
자본화:
|
볼륨(24시간):